Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharma company running the Phase III FLAMINGO-01 trial of Fast Track-designated GLSI-100, received a Nasdaq notice on May 20, 2026.
The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a late Form 10-Q for Q1 2026, but there is no immediate effect on GLSI’s Nasdaq Capital Market listing or trading.
Loading...
Loading translation...
Positive
Nasdaq notice has no immediate effect on GLSI listing or trading
Common stock continues trading on the Nasdaq Capital Market under symbol GLSI
Company highlights ongoing Phase III FLAMINGO-01 trial of GLSI-100 with Fast Track status
Negative
Company is not in compliance with Nasdaq Listing Rule 5250(c)(1)
Late filing of Form 10-Q for quarter ended March 31, 2026
News Market Reaction – GLSI
-0.94%
2 alerts
-0.94%Session close to close
$395.20MMarket Cap
0.1xRel. Volume
In the May 26 session, GLSI declined 0.94%, reflecting a mild negative market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights another Nasdaq notice tied to untimely SEC filings, this time for the F...
Analysis
This announcement highlights another Nasdaq notice tied to untimely SEC filings, this time for the Form 10-Q for the quarter ended March 31, 2026. The notice has no immediate effect on GLSI’s Nasdaq Capital Market listing. In context of prior delays for the Form 10-K and ongoing Phase III FLAMINGO-01 work with Fast Track GLSI-100, key items to watch include the timing of audited financials, updated cash figures, and any further listing-compliance communications.
Key Figures
Share price:$27.65Daily change:-0.48%Today’s volume:73,580 shares+5 more
8 metrics
Share price$27.65GLSI price before/around late Form 10-Q notice
Daily change-0.48%24h price change on low-volume session
Today’s volume73,580 sharesVersus 20-day average volume of 120,631 shares
52-week range$7.78 – $34.10Price vs 52-week low and high
R&D 2025$17.5 millionResearch and development expense for year ended Dec 31, 2025
R&D 2024$12.9 millionResearch and development expense for year ended Dec 31, 2024
Cash balance$10.5 millionUnaudited cash as of Mar 31, 2026 from prior update
Short interest23.19%Short percent of float with 13.05 days to cover
ATM-driven financing update and preliminary cash balance for Q1 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows positive clinical or conference news sometimes met with negative price reactions, while regulatory or filing updates have produced both gains and declines.
Recent Company History
Over the last few months, GLSI has reported multiple filing delays and clinical updates. Nasdaq notices for late Form 10-K and today’s late Form 10-Q reflect ongoing reporting challenges. In contrast, Phase III FLAMINGO-01 data and conference abstracts highlighted immune-response signals, yet reactions were sometimes negative. A financing update indicated an approximate cash balance of $10.5 million as of March 31, 2026. Together, the record shows a mix of operational progress and regulatory timing issues shaping sentiment.
Key Terms
form 10-q, nasdaq listing rule 5250(c)(1), fast track, immunotherapy, +4 more
8 terms
form 10-qregulatory
"because it has not yet filed its Quarterly Report on Form 10-Q for the three months..."
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
nasdaq listing rule 5250(c)(1)regulatory
"the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1)..."
Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.
fast trackregulatory
"evaluating Fast Track designated GLSI-100, an immunotherapy to prevent..."
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
immunotherapymedical
"GLSI-100, an immunotherapy to prevent breast cancer recurrences..."
Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.
phase iiimedical
"a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01..."
A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.
nasdaq capital marketregulatory
"continues to trade on the Nasdaq Capital Market under the symbol "GLSI.""
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
quarterly reportregulatory
"because it has not yet filed its Quarterly Report on Form 10-Q for the three months..."
A quarterly report is a company's regular financial update, issued every three months, that summarizes key numbers like sales, profits, cash flow and management’s brief commentary on operations. Investors use it like a report card or car dashboard: it shows recent performance, highlights trends or problems, and helps decide whether the stock’s price and future prospects justify buying, holding or selling.
securities and exchange commissionregulatory
"requires timely filing of periodic financial reports with the Securities and Exchange Commission."
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS.
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447) Email: dave@redchip.com
FAQ
What Nasdaq notice did Greenwich LifeSciences (GLSI) receive on May 20, 2026?
Greenwich LifeSciences received a Nasdaq notice that it is not in compliance with Listing Rule 5250(c)(1). According to Greenwich, the notice stems from the company’s failure to timely file its Form 10-Q for the quarter ended March 31, 2026.
Why is Greenwich LifeSciences (NASDAQ: GLSI) not in compliance with Nasdaq Listing Rule 5250(c)(1)?
Greenwich LifeSciences is out of compliance because it has not yet filed its Form 10-Q for Q1 2026. According to Greenwich, Listing Rule 5250(c)(1) requires timely filing of periodic financial reports with the US Securities and Exchange Commission.
Does the Nasdaq non-compliance notice affect trading of Greenwich LifeSciences (GLSI) stock?
The notice has no immediate effect on the listing or trading of GLSI stock. According to Greenwich, its common shares continue to trade on the Nasdaq Capital Market under the symbol GLSI despite the current reporting non-compliance.
What reporting obligation did Greenwich LifeSciences miss for Q1 2026?
Greenwich LifeSciences did not file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. According to Greenwich, this delayed filing caused non-compliance with Nasdaq Listing Rule 5250(c)(1) regarding timely submission of periodic SEC reports.
What is GLSI-100 and the FLAMINGO-01 Phase III trial mentioned by Greenwich LifeSciences (GLSI)?
GLSI-100 is an immunotherapy being evaluated to prevent breast cancer recurrences in the FLAMINGO-01 Phase III trial. According to Greenwich, GLSI-100 has Fast Track designation, underscoring the company’s clinical-stage focus despite its current Nasdaq reporting non-compliance.
Is Greenwich LifeSciences (GLSI) still listed on the Nasdaq Capital Market after the May 2026 notice?
Yes, Greenwich LifeSciences remains listed on the Nasdaq Capital Market following the notice. According to Greenwich, the Nasdaq notification regarding late Form 10-Q filing has no immediate effect on the listing or trading of its GLSI common stock.
